Skip to main content

Table 2 Summary of culture characteristics with rocking motion bioreactors

From: Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy

  Protocol features Starting material Reactor configuration
Author –Year IL-2 [IU/mL] Stimulation strategy Medium Serum and supplements Source Seed concentration [cells/mL] Bag volume [L] Culture volume [mL] System Rocks per minute Air flow [L/min] Rocking Angle [°] Feeding strategy
T CELLS
Hami [98] - 2004 Useda CD3 and CD28 beads Xvivo 15 CD3+ T cells from PBMC 20 Wave Bioreactor System 20XE Perfusion
Tran [66] - 2007 50 Irradiated PBMCs (APCs) RPMI 10% FBS; HEPES, GLN and Glucose CD4+ T cells from PBMC   Wave bioreactor system 2/10 EH 10–12 0.1 4 Perfusion: Media to keep GLN at 2 mM and glucose > 2 g/L.
Hollyman [99] - 2009 100–500 Preb - CD3/CD28 beads Xvivo 15 5% AB CD3+ from PBMCs 2 WAVE EHT Bioreactor 6–15   Perfusion: Volume increased over 24 h periods (200–1600 mL/day)
Janas [100] - 2015 20 [ng/mL] Pre - CD3/CD28 beads Xvivo 10 5% HS; GLN T cells from PBMCs 5.0 × 106 1000 W25 or W5 Xuri cell expansion system 15 6 Perfusion: < 2 × 106 cells/mL–0 mL/day; 2–10 × 106 cells/mL–500 mL/day; 10–15 × 106 cells/mL–750 ml/day; > 15 × 106 cells/mL–1000 mL/day
Vavrova [101] - 2016 20 Pre - Ag-mDCs (APCs); CD3/CD28 beads RPMI 5% AB; GLN, Ne AAs, BME, Pyruvate T cells from PBMCs 2 WAVE bioreactor 2/10 system 6 6 Media fed: maintain cell concentration in the 0.5–1 × 106 cells/mL range
O’hanlon [102] - 2017 200 Pre PHA IMDM 10% AB; GLN and glucose T cells from PBMCs 2.5–5.0 × 105 2 1000 Wave 2/10 (Xuri W5) 5–10 Perfusion: Culture days 1–2: 250 mL; Culture days 3–5: 500 mL
 McCartney [57] - 2019 350 Xuri T CEM 5% AB T cells from PBMCs 2 1000 Xuri Cell Expansion System 10 6 Perfusion: < 2 × 106 cells/mL–0 mL/day; 2–10 × 106 cells/mL–500 mL/day; 10–15 × 106 cells/mL–750 ml/day; > 15 × 106 cells/mL–1000 mL/day
Smith [103] - 2019 200–500 Pre anti CD3/CD28/CD2 Xuri T CEM 5% HS Tcells from PBMCS 1.0 × 106 2 Xuri Cell Expansion System W25 10 6 Perfusion: < 2 × 106 cells/mL–0 mL/day; 2–10 × 106 cells/mL–500 mL/day; 10–15 × 106 cells/mL–750 ml/day; > 15 × 106 cells/mL–1000 mL/day
NK CELLS
Sutlu [94] - 2010 500 OKT3 SCGM 5% HS PMBC 2.0 × 106 from 800 Wave Bioreactor System 2/10 6 0.1 6 Media fed: 300 mL/day when 3 e6 cells/mL when 7 e6 cells/mL, 500 mL/day; 1 e7 cells/mL, 750 mL/day; 2.5 e7, 1 L/day.
Spanholtz [104] - 2011 Useda GM-CSF. G-CSF, IL-6, IL-7, IL-15 GBGM 10% HS CD34+ UCB 1.0 × 106 from 250 WAVE Bioreactor System 2/10 and BIOSTATH CultiBag RM 10 0.1–0.2 6 Media addition to adjust cell density
 Rujkijyanont [105] - 2013 500 CD56- (APCs); IL15 OKT3 SCGM 5% AB CD56+ from PBMCs 1.0 × 106 2–20 from 200 WAVE Bioreactor 5–9 Media addition to adjust cell density
Lapteva [106] - 2014 500 K562-41BBL-mbIL-15 (APCs) SCGM 10% FBS CD56+ from PBMCs 2.0 × 105 WAVE Bioreactor 6 6
Meng [97] - 2018 Useda Pre OK-432 Xvivo 15 1% AP PBMC 3 3000 GE Xuri W25 7 6 Perfusion (parameters not specified)
TILs
Sadeghi [107] - 2011 600 PBMCs (APCs); OKT3 RPMI 5% AB; GLN 12 mM, 25 mM HEPES; BME TIL 5–10.0 × 107 (TOTAL) 2 1000 Wave Bioreactor System 2/10 (GE) 10 6 Perfusion: 350–1000 mL/day to maintain glucose and GLN in a range of 1.5–2 g/L and ~ 2–4 mM, respectively.
 Somerville [64] - 2012 3000 Pre – allogenic APCs, anti-CD3 AIMV 5% AB; 0,02% pluronic TIL/PBL 1500 WAVE bioreactor 2/10 system 7 6 Perfusion: maintain glucose concentration at ~ 170 mg/dL.
Donia [108] - 2014 6000 Pre - allogeneic APCs, antiCD3 AIMV Pluronic TIL 10   WAVE bioreactor 2/10 system 10 0.2 6 1000–4000 mL/day
  1. aUsed: stimulant was used but the amount was not specified. bPre: the stimulant was added to the culture prior to bioreactor expansion